コンテンツにジャンプ
先端医療開発センター

トップページ > グループ紹介 > 免疫療法開発分野(柏) > 業績

業績

2020年

  1. Nakajima H, Nakatsura T. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy. Immunological Medicine, 9:1-6, 2020
  2. Daiko H, Marafioti T, Fujiwara T, Shirakawa Y, Nakatsura T, Kato K, Puccio I, Hikichi T, Yoshimura S, Nakagawa T, Furukawa M, Stoeber K, Nagira M, Ide N, Kojima T. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients. Cancer Immunology, Immunotherapy. 2020 Jun 4. doi: 10.1007/s00262-020-02619-3. Online ahead of print.
  3. Taniguchi M, Mizuno S, Yoshikawa T, Fujinami N, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Nakatsura T. Peptide vaccine as an adjuvant therapy for glypican-3 positive hepatocellular carcinoma induces peptide specific CTLs and improves. Cancer Science. 2020 May 24. doi: 10.1111/cas.14497. Online ahead of print.
  4. Akazawa Y, Saito Y, Yoshikawa T, saito K, Nosaka K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T. Efficacy of immunotherapy targeting the neoantigen derived from EGFR T790M/C797S mutation in non-small cell lung cancer. Cancer Science.  2020 May 11. doi: 10.1111/cas.14451. Online ahead of print.
  5. Ueda T, Kumagai A, Iriguchi S, Yasui Y, Miyasaka T, Nakagoshi K, Nakane K, Saito K, Takahashi M, Sasaki A, Yoshida S, Takasu N, Seno H, Uemura Y, Tamada K, Nakatsura T, Kaneko S. Non-clinical efficacy, safety, and stable clinical cell processing of iPSC-derived anti-GPC3 CAR-expressing NK/ILC cells. Cancer Science. 111(5):1478-1490, 2020
  6. Miura M, Fujinami N, Shimizu Y, Mizuno S, Saito K, Suzuki T, Konishi M, Takahashi S, Gotohda N, Suto K, Yoshida T, Nakatsura T. Usefulness of plasma full-length GPC3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery. Oncology Letters. 19:2657-2666, 2020
  7. Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, Toyoda H, Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T. Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer Science. 111(2):334-342, 2020
  8. Imaizumi K, Suzuki T, Kojima M, Shimomura M, Sakuyama N, Tsukada Y, Sasaki T, Nishizawa Y, Taketomi A, Ito M, Nakatsura T. Ki67 expression and localization of T-cells after neoadjuvant therapies as reliable predictive markers in rectal cancer. Cancer Science. 111(1):23-35, 2020

2019年

  1. Akazawa Y, Hosono A, Yoshikawa T, Kaneda H, Nitani C, Hara J, Kinoshita Y, Kohashi K, Manabe A, Fukutani M, Wakabayashi M, Sato A, Shoda K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T. Efficacy of the NCCV Cocktail-1 vaccine for refractory pediatric solid tumors: a phase I clinical trial. Cancer Science. 110(12):3650-3662, 2019
  2. Tsuchiya N, Zhang R, Iwama T, Ueda N, Liu T, Tatsumi M, Sasaki Y, Shimoda R, Osako Y, Sakaue-Sawano A, Sawada Y, Negishi H, Kimura Y, Kubo Y, Miyashita A, Fukushima S, Nakaki R, Takubo K, Okada S, Miyawaki A, Kaneko S, Ihn H, Taniguchi T, Kaisyo T, Nishimura Y, Senju S, Endo I, Nakatsura T, Uemura Y. Type I Interferon Delivery by iPSC-derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. Cell Reports, 29(1):162-175, 2019
  3. Shimizu Y, Yoshikawa T, Kojima T, Shoda K, Nosaka K, Mizuno S, Wada S, Fujimoto Y, Sasada T, Kohashi K, Bando H, Endo I, Nakatsura T. Heat shock protein 105 peptide vaccine could induce anti-tumor immune reactions in a phase I clinical trial. Cancer Science. 110(10):3049–3060, 2019
  4. Shitara K, Ueha S, Shichino S, Aoki H, Ogiwara H, Nakatsura T, Suzuki T, Shimomura M, Yoshikawa T, Shoda K, Kitano S, Yamashita M, Nakayama T, Sato A, Kuroda S, Wakabayashi M, Nomura S, Yokochi S, Ito S, Matsushima K, Doi T. First-in-human phase 1 study of IT1208, a defucosylated humanized anti-CD4 depleting antibody, in patients with advanced solid tumors. J Immunother Cancer. 7(1):195. 2019
  5. Zhang R, Kitayama S, Liu T, Ueda N, Tokumitsu Y, Mashima H, Ohdan H, Kaneko S, Uemura Y. In vitro detection of cellular adjuvant properties of human invariant natural killer T cells. Methods in Molecular Biology. 2048:121-130, 2019
  6. Shimizu Y, Suzuki T, Yoshikawa T, Endo I, Nakatsura T. Next-generation cancer immunotherapy targeting glypican-3. Frontiers in Oncology. 9:248, 2019
  7. Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Scientific Reports. 9(1):5925, 2019
  8. Shimizu Y, Nakatsura T. Glypican-3: Hepatocellular carcinoma specific antigen, a novel target for cancer immunotherapy. Liver and Glycosylation. Glycoforum. Vol.22(1),2019
  9. Okada M, Tada Y, Seki T, Tohyama S, Fujita J, Suzuki T, Shimomura M, Ofuji K, Kishino Y, Nakajima K, Tanosaki S, Someya S, Kanazawa H, Senju S, Nakatsura T, Fukuda K. Selective limination of Undifferentiated Human Pluripotent Stem Cells Using Pluripotent State-Specific Immunogenic Antigen Glypican-3. Biochem. Biophys. Res. Comm. 511(3):711-717, 2019
  10. Akazawa Y, Suzuki T, Yoshikawa T, Mizuno S, Nakamoto Y, Nakatsura T. Prospects for immunotherapy as a novel therapeutic strategy against hepatocellular carcinoma. World Journal of Meta-Analysis. (review) 7(3);80-95, 2019
  11. Akazawa Y, Nobuoka D, Takahashi M, Yoshikawa T, Shimomura M, Yagi T, Fujiwara Y, Nakamoto Y, Nakatsura T. Higher human lymphocyte antigen class I expression in early‐stage cancer cells leads to high sensitivity for cytotoxic T lymphocytes. Cancer Science. 110(6):1842-1852. 2019

2018年

  1. Minagawa A, Yoshikawa T, Yasukawa M, Hotta A, Kunitomo M, Iriguchi S, Takiguchi M, Kassai Y, Imai E, Yasui Y, Kawai Y, Zhang R, Uemura Y, Miyoshi H, Nakanishi M, Watanabe A, Hayashi A, Kawana K, Fujii T, Nakatsura T, Kaneko S. Enhancing T Cell Receptor Stability in Rejuvenated iPSC-Derived T Cells Improves Their Use in Cancer Immunotherapy. Cell Stem Cell. 23(6):850-858, 2018
  2. Takahashi D, Kojima M, Suzuki T, Sugimoto M, Kobayashi S, Takahashi S, Konishi M, Gotohda N, Ikeda M, Nakatsura T, Ochiai A, Nagino M. Profiling the Tumour Immune Microenvironment in Pancreatic Neuroendocrine Neoplasms with Multispectral Imaging Indicates Distinct Subpopulation Characteristics Concordant with WHO 2017 Classification. Sci Rep. 8(1):13166, 2018
  3. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. In vitro hematopoietic differentiation from pluripotent stem cells or by direct lineage conversion: current advances and challenges. Journal of medical and biological engineering. 38(2):186-196, 2018
  4. Shimizu Y, Suzuki T, Yoshikawa T, Tsuchiya N, Sawada Y, Endo I, Nakatsura T. Cancer Immunotherapy Targeted Glypican-3 or Neoantigens. Cancer Sci. 109(3):531-541, 2018
  5. Ueda N, Uemura Y, Zhang R, Kitayama S, Iriguchi S, Kawai Y, Yasui Y, Tatsumi M, Ueda T, Liu TY, Mizoro Y, Okada C, Watanabe A, Nakanishi M, Senju S, Nishimura Y, Kuzushima K, Kiyoi H, Naoe T, Kaneko S. Generation of TCR expressing innate lymphoid-like helper cells that induces cytotoxic T cell-mediated anti-leukemia cell response. Stem Cell Reports. 10:213-227, 2018.
  6. Ueda N, Zhang R, Tatsumi M, Liu TY, Kitayama S, Yasui Y, Sugai S, Iwama T, Senju S, Okada S, Nakatsura T, Kuzushima K, Kiyoi H, Naoe T, Kaneko S, Uemura Y. BCR-ABL-specific CD4+ T-helper cells promote the priming of antigen-specific cytotoxic T cells via dendritic cells. Cell Mol Immunol. 15(1):15-26. 2018
  7. Wu L, Liu H, Guo H, Wu Q, Yu S, Qin Y, Wang G, Wu Q, Zhang R, Wang L, Zhang L, Liu L, Jiao S, Liu T. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett. 15: 9507-9515, 2018.

2017年

  1. Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, Wu L, Yu S, Shi F, Li Y, Zhang L, Wang L, Feng S, Zhang Q, Peng Y, Wu Q, Liu C, Chang X, Yang L, Uemura Y, Yu X, Liu T. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 411:182-190, 2017
  2. Tsuchiya N, Yoshikawa T, Fujinami N, Saito K, Mizuno S, Sawada Y, Endo I, Nakatsura T. Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma. OncoImmunology. 6(10):e1346764, 2017
  3. Tsuchiya N, Hosono A, Yoshikawa T, Shoda K, Nosaka K, Shimomura M, Hara J, Nitani C, Manabe A, Yoshihara H, Hosoya Y, Kaneda H, Kinoshita Y, Kohashi K, Yoshimura K, Fujinami N, Saito K, Mizuno S, Nakatsura T. Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors. OncoImmunology.  7(1):e1377872, 2017
  4. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. Rejuvenation of Cardiac Tissue Developed from Reprogrammed Aged Somatic Cells. Rejuvenation Res. 20(5):389-400. 2017
  5. Ofuji K, Saito K, Suzuki S, Shimomura M, Shirakwa H, Nobuoka D, Yawada Y, Yoshimura M, Tsuchiya N, Takahashi M, Yoshikawa T, Tada Y, Konishi M, Takahashi S, Gotohda N, Nakamoto Y, Nakatsura T. Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma. Oncotarget. 8(23): 37835-44, 2017
  6. Shi F, Guo H, Zhang R, Liu H, Wu L, Wu Q, Liu J, Liu T, Zhang Q. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temolomide in GBM cell lines. Neuroscience, 29;346:298-308, 2017
  7. Cheng Z, Peng HL, Zhang R, Fu XM, Zhang GS. Bone marrow-derived innate macrophages attenuate oxazolone-induced colitis. Cell Immunol. 311:46-53, 2017

2016年

  1. Suzuki S, Sakata J, Utsumi F, Sekiya R, Kajiyama H, Shibata K, Kikkawa F, Nakatsura T. Efficacy of Glypican-3-derived Peptide Vaccine Therapy on the Survival of Patients with Refractory Ovarian Clear Cell Carcinoma. OncoImmunology. 5(11) ;e1238542, 2016
  2. Sugai S, Yoshikawa T, Iwama T, Tsuchiya N, Ueda N, Fujinami N, Shimomura M, Zhang R, Kaneko S, Uemura Y, Nakatsura T. Hepatocellular carcinoma cell sensitivity to Vg9Vd2 T lymphocyte-mediated killing is increased by zoledronate. Int. J. Oncol. 48: 1794-1804, 2016
  3. Kitayama S, Zhang R, Liu T-Y, Ueda N, Iriguchi S, Yasui Y, Kawai Y, Tatsumi M, Hirai N, Mizoro Y, Iwama T, Watanabe A, Nakanishi M, Kuzushima K, Uemura Y, Kaneko S. Cellular adjuvant properties and direct cytotoxicity of redifferentiated Va24 invariant NKT-like cells from human induced pluripotent stem cells. Stem Cell Reports. 6 (2): 213-227, 2016
  4. Nakatsuka R, Iwaki R, Matsuoka Y, Sumide K, Kawamura H, Fujioka T, Sasaki Y, Uemura Y, Asano H, Kwon A-H, Sonoda Y. Identification and characterization of Lineage-CD45-Sca-1+ VSEL phenotypic residing in adult mouse bone tissue. Stem Cells and Development. 25: 27-42, 2016.
  5. Fujinami N, Yoshikawa T, Sawada Y, Shimomura M, Iwama T, Sugai S, Kitano S, Uemura Y, Nakatsura T. Enhancement of antitumor effect by peptide vaccine therapy in combination withanti-CD4antibody: Study in a murine model. Biochemistry and Biophysics Reports. 5;482-491,2016
  6. Sawada Y, Yoshikawa T, Ofuji K, Yoshimura M, Tsuchiya N, Takahashi M, Nobuoka D, Gotohda N, Takahashi S, Kato Y, Konishi M, Kinoshita T, Ikeda M, Nakachi K, Yamazaki N, Mizuno S, Takayama T, Yamao K, Uesaka K, Furuse J, Endo I, Nakatsura T. Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients. OncoImmunology. 5(5); e1129483,2016
  7. Iwama T, Uchida T, Sawada Y, Tsuchiya N, Sugai S, Shimomura M, Yoshikawa T, Zhang R, Uemura Y, Nakatsura T. Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice. Biochem. Biophys. Res. Comm. 469(1):138-43. 2016
  8. Mohammad A.S, Tomita Y, Yuno A, Hirayama M, Irie A, Tsukamoto H, Senju S, Yuba E, Yoshikawa T, Kono K, Nakatsura T, Nishimura Y. Identification of Glypican-3-Derived Long Peptides Activating both CD8+ and CD4+ T-cells; Prolonged Overall Survival in Cancer Patients with Th Cell Response. OncoImmunology. 2015 Aug 31;5(1):e1062209. eCollection 2016.

2015年

  1. Tsuchiya N, Sawada Y, Endo I, Uemura Y, Nakatsura T. Potentiality of immunotherapy against hepatocellular carcinoma, World J Gastroenterol. 21(36):10314-10326,2015(review)
  2. Tsuchiya N, Sawada Y, Endo I, Saito K, Uemura Y, Nakatsura T. Biomarkers for the early diagnosis of hepatocellular carcinoma, World J Gastroenterol. 21(37):10573-10583,2015(review)
  3. Sakamoto R, Rahman MM, Shimomura M, Itoh M, Nakatsura T. Time-Lapse Imaging Assay Using the Biostation CT: A Sensitive Drug-Screening Method for 3D Cell Culture. Cancer Sci. 106(6);757-765, 2015
  4. Zhang R, Liu T, Senju S, Haruta M, Hirosawa N, Suzuki M, Tatsumi M, Ueda N, Maki H, Nakatsuka R, Matsuoka Y, Sasaki Y, Tsuzuki S, Nakanishi H, Araki R, Abe M, Akatsuka Y, Sakamoto Y, Sonoda Y, Nishimura Y, Kuzushima K. Uemura Y. Generation of mouse pluripotent stem cell-derived proliferating myeloid cells as an unlimited source of functional antigen-presenting cells. Cancer Immunol. Res. 3 (6): 668-677 2015
  5. Matsuoka Y, Nakatsuka R, Sumide K, Kawamura H, Takahashi M, Fujioka T, Uemura Y, Asano H, Sasaki Y, Inoue M, Ogawa H, Takahashi T, Hino M, Sonoda Y. Prospectively isolated human bone marrow-derived MSCs support primitive human CD34-negative hematopoietic stem cells. Stem Cells. 33 (5): 1554-1565, 2015
  6. Nakatsuka R, Matsuoka Y, Uemura Y, Sumide K, Iwaki R, Takahashi M, Fujioka T, Sasaki Y, Sonoda Y. Mouse dental pulp stem cells support human umbilical cord blood-derived hematopoietic stem/progenitor cells in vitro. Cell Transplantation. 24: 97-113, 2015
  7. Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer. Int. J. Oncol. 46:497-504,2015
  8. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T. Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int. J. Oncol. 46:28-36,2015

2014年

  1. Ofuji K, Saito K, Yoshikawa T, Nakatsura T. Critical analysis of the potential of targeting GPC3 in hepatocellular carcinoma. J Hepatocell Carcinoma. 2014 21;1:35-42. doi: 10.2147/JHC. S48517. eCollection 2014. (review)
  2. Yoshikawa T, Takahara M, Tomiyama M, Nieda M, Maekawa R, Nakatsura T. Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy. Int. J. Oncol. 45:1847-1856,2014
  3. Yabusaki M, Sato J, Kohyama A, Kojima T, Nobuoka D, Yoshikawa T, Sawada Y, Murakami K, Gohda K, Okegawa T, Nakamura M, Takamatsu K, Ito M, Kaneko K, Nakatsura T. Detection and preliminary evaluation of circulating tumor cells in the peripheral blood of patients with eight types of cancer using a telomerase-specific adenovirus. Oncol. Rep. 32:1772-1778,2014
  4. Yoshimura M, Tada Y, Ofuzi K, Yamamoto M, Nakatsura T. Identification of a novel HLA-A* 02:01-restricted cytotoxic T lymphocyte epitope derived from the EML4-ALK fusion gene. Oncol. Rep. 32(1):33-39,2014
  5. Sawada Y, Komori H, Tsunoda Y, Shimomura M, Takahashi M, Baba H, Ito M, Saito N, Kuwano H, Endo I, Nishimura Y, Nakatsura T. Identification of HLA-A2 or HLA-A24-restricted CTL epitopes for potential HSP105-targeted immunotherapy in colorectal cancer. Oncol. Rep. 31(3):1051-1058,2014
  6. Suzuki S, Shibata K, Kikkawa F, Nakatsura T. Significant Clinical Response of Progressive Recurrent Ovarian Clear Cell Carcinoma to Glypican-3-derived Peptide Vaccine Therapy: Two Case Reports. Hum Vacc Immunother. 10(2):338-343,2014

2013年

  1. Tada Y, Yoshikawa T, Shimomura M, Sawada Y, Sakai M,Shirakawa H, Nobuoka D and Nakatsura T. Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinical response to vaccination with a glypican‑3‑derived peptide. Int. J. Oncol. 43(4):1019-1026,2013
  2. Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case.  Hum Vacc Immunother. 9(6):1228-1233,2013
  3. Nobuoka D, Yoshikawa T, Fujiwara T, and Nakatsura T.  Peptide intra-tumor injection for cancer immunotherapy:Enhancement of tumor cell antigenicity is a novel and attractive strategy. Hum Vacc Immunother. 9(6):1234-1236,2013
  4. Nobuoka D, Yoshikawa T, Takahashi M, Iwama T, Horie K, Shimomura M, Suzuki S, Sakemura N, Nakatsugawa M, Sadamori H, Yagi T, Fujiwara T, Nakatsura T. Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement of antigen-specific cancer immunotherapy. Cancer Immunol Immun. 62(4):639-652,2013
  5. Kondo S, Demachi-Okamura A, Hirosawa T, Maki H, Fujita M, Uemura Y, Akatsuka Y, Yamamoto E, Shibata K, Ino K, Kikkawa F, Kuzushima K. An HLA-modified ovarian cancer cell line induced CTL responses specific to an epitope derived from claudin-1 presented by HLA-A*24:02 molecules. Hum Immunol. 74: 1103-1110, 2013
  6. Nishimura T, Kaneko S, Kawana-Tachikawa A, Tajima Y, Gotoh H, Zhu D, Nakayama K, Iriguchi S, Uemura Y, Shimizu T, Takayama N, Yamada D, Nishimura K, Ohtaka M, Watanabe N, Takahashi S, Iwamoto A, Koseki H, Nakanishi M, Eto K, Nakauchi H. Generation of rejuvenated antigen-specific T cells by reprogramming to pluripotency and redifferentiation. Cell Stem Cell. 12: 114-126, 2013
  7. Iwama T, Horie K, Yoshikawa T, Nobuoka D, Shimomura M, Sawada Y, Nakatsura T. Identification of an H2-Kb or H2-Db restricted and glypican-3-derived cytotoxic T-lymphocyte epitope peptide. Int. J. Oncol. 42(3):831-838,2013
  8. Nobuoka D, Yoshikawa T, Sawada Y, Fujiwara T, Nakatsura T. Peptide vaccines for hepatocellular carcinoma. Hum Vacc Immunother. 9(1):210-212,2013

2012年

  1. Sawada Y, Sakai M, Yoshikawa T, Ofuji K , Nakatsura T. A glypican-3-derived peptide vaccine against hepatocellular carcinoma. OncoImmunology. 1(8):1448-1450,2012
  2. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M, Nakagori T, Takahashi S, Gotoda N, Takayama T, Yamao K, Uesaka K, Furuse J, Kinoshita T, Nakatsura T. Phase I trial of glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma : immunological evidence and potential for improving overall survival. Clin. Cancer Res. 18(13):3686-3696, 2012
  3. Nishio N, Fujita M, Tanaka Y, Maki H, Zhang R, Hirosawa T, Demachi-Okamura A, Uemura Y, Taguchi O, Takahashi Y, Kojima S, Kuzushima K. Zoledronate sensitizes neuroblastoma-derived tumor-initiating cells to cytolysis mediated by human γδ T cells. J. Immunother. 35: 598-606, 2012